FORM 4
[ X ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Hove Anders D 		2. Issuer Name and Ticker or Trading Symbol

Anacor Pharmaceuticals, Inc. [ ANAC ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      _____ 10% Owner
_____ Officer (give title below)      _____ Other (specify below)
(Last)          (First)          (Middle)

C/O VENROCK, 3340 HILLVIEW AVE 		3. Date of Earliest Transaction (MM/DD/YYYY)

6/24/2016
(Street)

PALO ALTO, CA 94304
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   6/24/2016     D    33886   (1) D $99.25   0   D   (2)  

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy)   $6.92   6/24/2016     D         30000      (1)   (1) Common Stock   30000     (1) 0   D   (3)  
Stock Option (right to buy)   $6.74   6/24/2016     D         15000      (1)   (1) Common Stock   15000     (1) 0   D   (3)  
Stock Option (right to buy)   $5.20   6/24/2016     D         12500      (1)   (1) Common Stock   12500     (1) 0   D   (3)  
Stock Option (right to buy)   $5.11   6/24/2016     D         15000      (1)   (1) Common Stock   15000     (1) 0   D   (3)  
Stock Option (right to buy)   $14.22   6/24/2016     D         15000      (1)   (1) Common Stock   15000     (1) 0   D   (3)  
Stock Option (right to buy)   $69.40   6/24/2016     D         4096      (1)   (1) Common Stock   4096     (1) 0   D   (3)  

Explanation of Responses:
( 1)  As of the effective time of the transactions contemplated by the Agreement and Plan of Merger, dated as of May 14, 2016 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Quattro Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent, pursuant to the terms of the Merger Agreement, (i) each share of the Issuer's Common Stock held by the reporting person was disposed of in exchange for the merger consideration of $99.25 per share, (ii) each award of restricted stock units and stock options became fully vested and (iii) each award of restricted stock units and stock options was cancelled in exchange for the right to receive a cash payment per share in an amount equal to $99.25 less, in the case of stock options, the applicable exercise price.
( 2)  The reporting person is a member of VR Management, LLC (the "Management Company"). Under an agreement between the reporting person and the Management Company, the reporting person is deemed to hold an aggregate of 794 of the reported securities for the sole benefit of the Management Company (the "Management Company Shares"). The Management Company may be deemed the indirect beneficial owner of the Management Company Shares, and the reporting person may be deemed the indirect beneficial owner of the Management Company Shares through his interest in the Management Company. The reporting person disclaims beneficial ownership of the Management Company Shares except to the extent of his indirect pecuniary interest therein.
( 3)  The reporting person is a member of VR Management, LLC. Under an agreement between the reporting person and the Management Company, the reporting person is deemed to hold the reported option for the sole benefit of the Management Company and must exercise the option solely upon the direction of the Management Company, which is entitled to the shares issued upon exercise. The Management Company may be deemed the indirect beneficial owner of the option, and the reporting person may be deemed the indirect beneficial owner of the option through his interest in the Management Company. The reporting person disclaims beneficial ownership of the option except to the extent of his pecuniary interest therein.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Hove Anders D
C/O VENROCK
3340 HILLVIEW AVE
PALO ALTO, CA 94304 		X



Signatures
/s/ David L. Stepp, Attorney-in-fact 6/24/2016
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more Anacor Pharmaceuticals, Inc. Charts.
Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more Anacor Pharmaceuticals, Inc. Charts.